Nonalcoholic fatty liver disease is the most common chronic liver disease in children and has become the leading indication for liver transplantation in adults. The primary treatment modality is lifestyle modification to promote weight loss, which is challenging to achieve and maintain. Adjunctive weight loss medications, such as topiramate, are commonly used off-label in adults and children with obesity and found to be safe and effective. We report an adolescent male with severe obesity and nonalcoholic steatohepatitis refractory to aggressive lifestyle intervention. He was safely treated with topiramate with resultant weight loss, reduction in body mass index z-score, improvement in liver enzymes, and resolution of hepatic steatosis. This is the first report of using topiramate in a pediatric patient with obesity and nonalcoholic steatohepatitis. Topiramate should be considered in pediatric nonalcoholic fatty liver disease to help curb emotional eating and promote satiety in cases refractory to lifestyle intervention alone.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191479PMC
http://dx.doi.org/10.1097/PG9.0000000000000126DOI Listing

Publication Analysis

Top Keywords

weight loss
16
liver disease
16
lifestyle intervention
12
nonalcoholic fatty
12
fatty liver
12
pediatric nonalcoholic
8
obesity nonalcoholic
8
nonalcoholic steatohepatitis
8
liver
6
nonalcoholic
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!